Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database

David Madigan, Jennifer Shin Department of Statistics, Columbia University, New York, NY, USA Introduction: Substantial evidence suggests that drospirenone-containing oral contraceptives may cause a higher risk of venous thrombotic events than earlier-generation oral contraceptives. Methods: To gain...

Full description

Bibliographic Details
Main Authors:	Madigan D, Shin J
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-04-01
Series:	Open Access Journal of Contraception
Subjects:	Drug safety Yaz Venous thrombotic events FDA Adverse Event Reporting System Disproportionality
Online Access:	https://www.dovepress.com/drospirenone-containing-oral-contraceptives-and-venous-thromboembolism-peer-reviewed-article-OAJC

Similar Items

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024-04-01)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023-06-01)

Signal mining and analysis for adverse events of avatrombopag based on FAERS
by: XIONG Rui, et al.
Published: (2024-02-01)

Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
by: Risako Hirai, et al.
Published: (2023-11-01)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
by: Xiaojiang Tian, et al.
Published: (2022-03-01)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023-04-01)

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety
by: Cheng Jiang, et al.
Published: (2024-02-01)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
by: Xiang Zhou, et al.
Published: (2021-12-01)

Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023-12-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system
by: Hongli Wang, et al.
Published: (2024-01-01)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
by: Kavanagh KT, et al.
Published: (2019-07-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

Evaluation of adverse events of CDK4/6 inhibitors: a real-world study based on the FAERS database
by: SHE Youjun, GUO Zihan, ZHANG Zhongwei, DU Qiong
Published: (2023-10-01)

Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data
by: Lingqing Ding, et al.
Published: (2024-02-01)

Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of <i>Clostridium difficile</i> Infection Associated with Antibacterial Drug Exposure
by: Dongxuan Li, et al.
Published: (2023-06-01)

Increased Susceptibility for Thromboembolic Events versus High Bleeding Risk Associated with COVID-19
by: Cristina Tudoran, et al.
Published: (2022-08-01)

Drug repositioning prediction for psoriasis using the adverse event reporting database
by: Minoh Ko, et al.
Published: (2023-03-01)

New Adverse Drug Reaction Signals from 2017 to 2021—Genuine Alerts or False Alarms?
by: Yoon Kong Loke, et al.
Published: (2024-02-01)

Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study
by: Lei Wang, et al.
Published: (2023-05-01)

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database
by: Shuang Xia, et al.
Published: (2024-01-01)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
by: Xue-Feng Jiao, et al.
Published: (2023-01-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Folate-containing antiandrogen oral contraceptives: dermatological aspects
by: S A Monakhov
Published: (2016-08-01)

Opioids and frequency counts in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database: a quantitative view of the epidemic
by: Veronin MA, et al.
Published: (2019-08-01)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
by: Han N, et al.
Published: (2021-08-01)

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
by: Hiroki Asano, et al.
Published: (2023-11-01)

Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database
by: LIANG Cuilyu, et al.
Published: (2022-11-01)

Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
by: Wenfang Sun, et al.
Published: (2024-01-01)

Hospital Length of Stay Is Associated With Increased Likelihood for Venous Thromboembolism After Total Joint Arthroplasty
by: Brett Salomon, MD, et al.
Published: (2021-04-01)

Rheumatoid arthritis and venous thromboembolic events
by: M. A. Satybaldyeva
Published: (2016-10-01)

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database
by: Mansour Tobaiqy, et al.
Published: (2021-04-01)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
by: Anne Schaefer, et al.
Published: (2020-04-01)

Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
by: Yifei Xue, et al.
Published: (2023-06-01)

Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events
by: Xiangmin Ji, et al.
Published: (2022-01-01)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
by: Yu Wang, BA, et al.
Published: (2020-09-01)

Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database
by: Feng Huang, et al.
Published: (2024-03-01)

Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database
by: Xiayang Ren, et al.
Published: (2024-01-01)

Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials
by: Li Wang, et al.
Published: (2024-01-01)